What happened with ELUT today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Elutia’s main commercial product is SimpliDerm, human donor skin tissue processed to remove cells and used in soft-tissue reconstruction. Its Women’s Health business supplies most revenue; a smaller cardiovascular business sells ProxiCor, VasCure and Tyke for cardiovascular repair. Elutia sells directly to healthcare facilities through independent sales agents, with its current sales concentrated in the United States. Hospitals pay for the products and seek reimbursement for the procedures, generally without separate payment for the materials, making purchasing decisions sensitive to procedure reimbursement and product prices.
The business depends on Berkeley, its sole supplier of SimpliDerm, and Cook Biotech, now owned by Evergen, its sole supplier of the porcine tissue material used in cardiovascular products. Those cardiovascular products also depend on licensed rights from Cook. Independent agents control customer relationships and can sell competing products.
Elutia has FDA clearance for its cardiovascular products. It markets SimpliDerm as a human tissue product without device clearance or biologics approval; if the FDA disagrees with that classification or certain uses, Elutia could need additional authorization to continue selling it.
Elutia sold its cardiac-device envelope business, including EluPro and CanGaroo, to Boston Scientific and Cardiac Pacemakers in October 2025. Its development strategy now principally focuses on NXT-41x, a tissue matrix intended to deliver antibiotics locally and reduce complications around implanted medical devices. This is a development program, not a current sales product, and commercialization depends on funding and FDA authorization.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Elutia’s results depend chiefly on SimpliDerm adoption and hospital access, with Berkeley its sole SimpliDerm supplier and Evergen-owned Cook Biotech its sole supplier of cardiovascular matrix material.
LeMaitre competes with Elutia for the same surgical buyers, selling biologic vascular patches against Elutia’s cardiovascular repair products. Their U.S. distribution agreement ended in May 2025, but the rivalry remains: watch LeMaitre’s biologic vascular patch sales for signs of competitive pressure on Elutia’s cardiovascular business.
LeMaitre Vascular, Inc. earningsLMAT
LeMaitre Vascular’s report will show whether its biologic vascular patches are gaining traction with the same surgical buyers and adding competitive pressure on Elutia’s cardiovascular repair products.
Compare LeMaitre Vascular’s disclosed biologic vascular patch sales with the trend in its broader vascular sales. If patch sales grow faster, the patches appear to be gaining ground with shared surgical buyers, which could increase competition for Elutia’s cardiovascular products; weak or lagging patch sales offer less evidence of pressure, but neither result alone proves that Elutia’s orders changed.
Elutia Inc. earningsThis company
Elutia’s report will show whether sales and product margins from SimpliDerm and its cardiovascular repair products are gaining ground against the costs of running the business.
Read Women’s Health and Cardiovascular sales alongside gross margin—the share of sales left after product costs—and operating expenses. Rising sales with a steady margin and expenses that do not swell as fast would show direct selling is helping the product businesses scale; weaker sales or margins against high expenses would show those businesses still cannot carry the cost base.
